The present study has identified clinically relevant alterations in the tumor immune microenvironment, where intratumoral cell–cell interactions between marker-defined CD11c+ APCs and CD8+ T cells emerged as a novel prognostic marker associated with superior patient survival in STS. This evidence concerns the gene CD8A and telomere syndrome.